+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating treatments for adults with high risk chronic lymphocytic leukemia CLL, a common and aggressive form of leukemia. The study compares a triple drug combination of acalabrutinib, obinutuzumab, and venetoclax GAVe against a dual combination of obinutuzumab and venetoclax GVe. This phase 3 trial aims to see if adding acalabrutinib can prolong the time patients live without disease progression, focusing on patients with specific genetic risk factors like 17p deletion, TP53 mutation, or complex karyotype. Participants receive infusions of obinutuzumab on specific days during the first six cycles, along with oral venetoclax taken daily with increasing doses during the initial cycles and then a fixed dose for up to 12 cycles. Those in the triple combination group also take oral acalabrutinib twice daily for cycles 15 to 24. Treatments are given in cycles lasting several weeks, with precise dosing schedules for each medication. During the study, participants undergo regular assessments including blood tests to monitor disease status and treatment effects. Researchers measure progression-free survival as the primary outcome, along with other outcomes such as minimal residual disease, overall response, survival rates, and time until next treatment. The study involves randomized assignment to treatment groups and continues through multiple cycles, with monitoring extending up to 50 months after the first patient is included.

Age: 18Years - 120YearsAll GendersPhase 3
30 locations
R

Actively Recruiting

Researchers are conducting a registry study involving adult patients diagnosed with acute myeloid leukemia AML and related myeloid neoplasms, including newly diagnosed or relapsedrefractory cases. The study aims to collect comprehensive data on patient characteristics, family history, biological disease profiles, and clinical outcomes. It also focuses on analyzing disease-related genetic markers and the impact of measurable residual disease MRD using various methods. The study does not involve specific treatments but collects data and biological samples such as bone marrow, blood, plasma, and normal tissue including skin biopsies and other specimens. This observational study enrolls patients from around 80 to 90 sites in Germany and Austria. Patients treatment responses, decisions, and outcomes are tracked over time. Participants are observed for up to 10 years, during which researchers gather information on treatment response, survival, relapse rates, quality of life, and genetic markers. The study includes assessments of event-free survival, relapse-free survival, cumulative incidence of relapse and death, and overall survival. Patient consent is required for registration, data storage, and biobanking of specimens for analysis throughout the observation period.

Age: 18Years +All Genders
94 locations
C

Actively Recruiting

Researchers are evaluating how well Rina-S GEN1184 works compared to standard chemotherapy treatments chosen by a physician for women with recurrent or progressive endometrial cancer who have had prior therapy. This randomized, open-label Phase 3 study involves about 660 participants and aims to assess progression-free survival and overall survival over approximately three years. The study is sponsored by Genmab and focuses on treatment after platinum-based chemotherapy and PDL-1 therapy. Participants are randomly assigned to one of two groups one group receives Rina-S intravenously every three weeks, and the other receives one of two chemotherapy drugspaclitaxel on days 1, 8, and 15 every four weeks, or doxorubicin on day 1 every three weekschosen by the investigator before randomization. Treatment duration varies but typically lasts between 4 to 6 months. No participants receive placebo all receive an active drug. Throughout the study, participants will visit study sites regularly for treatment and monitoring. Researchers will conduct evaluations including imaging scans to assess tumor response, monitor health status and quality of life, and track any treatment-related side effects. These assessments will continue for up to about three years to measure outcomes like progression-free survival and overall survival, ensuring close safety monitoring and comprehensive data collection during the participation period.

Age: 18Years +FEMALEPhase 3
178 locations